The next generation biopharmaceuticals

Interim Report – January to March 2021

2021-05-14

Interim Report – January to March 2021

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today issued its First Quarter Report for 2021.

Financial Highlights

  • Revenue for the 1st Quarter 2021 amounted to SEK 15.2 (9.6) m
  • Operating result for the quarter amounted to SEK -91.9 (-58.2) m
  • Net result for the quarter amounted to SEK -93.2 (-58.9) m
  • Cash flow for the quarter amounted to SEK -94.6 (-78.4) m
  • Cash and cash equivalents at the end of the period amounted to SEK 41.3 (296.4) m

Significant Events during the Reporting Period

  • On February 10 2021, Affibody AB and Inmagene Biopharmaceuticals announced that the U.S. FDA has cleared izokibep (ABY-035) to proceed to Phase 2 clinical development in Ankylosing Spondylitis (AS), a subset of Axial Spondyloarthritis (axSpA). 
  • On March 9 2021, Affibody AB and Inmagene Biopharmaceuticals announced that the U.S. FDA has cleared the novel interleukin-17 (IL-17) blocker izokibep (ABY-035) to proceed to Phase 2 clinical development in non-infectious intermediate, posterior, and pan-uveitis.

Significant Events after the close of the Reporting Period

  • On May 3 2021 Affibody Medical AB (publ) received a SEK 100.0 m loan from its major shareholder Duba AB, a subsidiary within the Investor group.

Affibody is a clinical stage biopharmaceutical company with a broad product pipeline focused on developing innovative bi- and multi-specific next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

The company operates a focused experimental medicine model and currently has two clinical stage programs. The first is a therapeutic program that targets psoriasis. The second program is a diagnostic imaging program that is directed primarily towards metastatic breast cancer.

Affibody AB is a holding of Patricia Industries.

Further information can be found at: www.affibody.com

Affibody in short

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

Upcoming reports Financial calendar

  • Interim Report January to March 2020 (May 15, 2020)
  • Interim Report January to June 2020 (August 21, 2020)
  • Interim Report January to September 2020 (November 13, 2020)
  • Year End Report 2020 (February 2021)